Ketoconazole - indications restricted

Several of the indications for Nizoral (ketoconazole) 200mg tablets have been removed due to a risk of serious hepatotoxicity.

Following a systematic review of available data, therapeutic use is now restricted to patients resistant to, or intolerant of, other effective antifungal therapies.

The following indications have been removed from the Summary of Product Characteristics (SPC):
- chronic, recurrent vaginal candidosis
- systemic fungal infections
- prophylaxis of mycotic infections in patients with reduced immune responses
- systemic candidosis
- culturally determined dermatophyte infections of fingernails
- oesophageal candidosis
- treatment of paracoccidioidomycosis, histoplasmosis, coccidioidmycosis and blastomycosis.

The updated SPC also includes new warnings about the duration of treatment (thought to be the main risk factor for serious hepatotoxicity), monitoring requirements for hepatic function (before and during treatment), the addition of drugs that are contraindicated for use with ketoconazole and new post-marketing adverse effects

Further information: MHRA

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Vitamin D3 Supplements

Formulations and indications of colecalciferol preparations.

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Avoid gout drug in patients with major cardiovascular conditions, says MHRA

Treatment with febuxostat (Adenuric) should be avoided...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Colestid Orange. Use our constantly updated...

Updated bowel disease treatment summaries published by MIMS

Updated bowel disease treatment summaries published by MIMS

Updated quick-reference summaries of the latest NICE...